- Home
- ALLE vs QGEN Comparison
ALLE vs QGEN Comparison
Compare ALLE & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLE
- QGEN
- Stock Information
- Founded
- ALLE 2013
- QGEN 1986
- Country
- ALLE Ireland
- QGEN Netherlands
- Employees
- ALLE N/A
- QGEN N/A
- Industry
- ALLE Diversified Commercial Services
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLE Consumer Discretionary
- QGEN Health Care
- Exchange
- ALLE Nasdaq
- QGEN Nasdaq
- Market Cap
- ALLE 10.6B
- QGEN 9.1B
- IPO Year
- ALLE N/A
- QGEN 1996
- Fundamental
- Price
- ALLE $141.86
- QGEN $41.86
- Analyst Decision
- ALLE Hold
- QGEN Buy
- Analyst Count
- ALLE 5
- QGEN 8
- Target Price
- ALLE $140.40
- QGEN $50.53
- AVG Volume (30 Days)
- ALLE 940.9K
- QGEN 1.3M
- Earning Date
- ALLE 04-24-2025
- QGEN 05-07-2025
- Dividend Yield
- ALLE 1.44%
- QGEN 3.15%
- EPS Growth
- ALLE 16.19
- QGEN N/A
- EPS
- ALLE 7.12
- QGEN 0.42
- Revenue
- ALLE $3,820,200,000.00
- QGEN $2,002,874,000.00
- Revenue This Year
- ALLE $4.34
- QGEN $4.89
- Revenue Next Year
- ALLE $4.34
- QGEN $6.41
- P/E Ratio
- ALLE $19.90
- QGEN $100.26
- Revenue Growth
- ALLE 5.48
- QGEN 3.31
- 52 Week Low
- ALLE $113.27
- QGEN $37.63
- 52 Week High
- ALLE $156.10
- QGEN $47.93
- Technical
- Relative Strength Index (RSI)
- ALLE 66.13
- QGEN 50.87
- Support Level
- ALLE $139.11
- QGEN $42.04
- Resistance Level
- ALLE $142.53
- QGEN $43.46
- Average True Range (ATR)
- ALLE 2.62
- QGEN 0.83
- MACD
- ALLE 0.72
- QGEN -0.10
- Stochastic Oscillator
- ALLE 96.35
- QGEN 17.95
About ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).